{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:44:31Z","timestamp":1791690271475,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005683","name":"Kyoto University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.035","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:10:31Z","timestamp":1609287031000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade"],"prefix":"10.1016","volume":"144","author":[{"given":"Hironori","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-3751","authenticated-orcid":false,"given":"Hiroaki","family":"Ozasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5706-8300","authenticated-orcid":false,"given":"Takahiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Funazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-4119","authenticated-orcid":false,"given":"Yuto","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Ajimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Yamazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomitsu","family":"Kuninaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ogimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-7884","authenticated-orcid":false,"given":"Ryo","family":"Itotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyohiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.035_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.035_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.035_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.11.035_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.11.035_bib5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.035_bib6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.11.035_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.11.035_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.035_bib9","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.11.035_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejca.2020.11.035_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.11.035_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2020.11.035_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2017.136","article-title":"Hallmarks of response to immune checkpoint blockade","volume":"117","author":"Cogdill","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.11.035_bib14","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm.3897","article-title":"Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies","volume":"21","author":"Cho","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2020.11.035_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrg3502","article-title":"Genetic insights into common pathways and complex relationships among immune-mediated diseases","volume":"14","author":"Parkes","year":"2013","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.ejca.2020.11.035_bib16","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1210\/jc.2009-1404","article-title":"Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility","volume":"94","author":"Mitchell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2020.11.035_bib17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/art.20040","article-title":"Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus","volume":"50","author":"Lin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejca.2020.11.035_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.prp.2018.12.002","article-title":"Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: a systematic review and meta-analysis","volume":"215","author":"Zou","year":"2019","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ejca.2020.11.035_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.gene.2018.06.069","article-title":"Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population","volume":"674","author":"Xie","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.ejca.2020.11.035_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3390\/cancers11081150","article-title":"Association between PD-1 and PD-L1 polymorphisms and the risk of cancer: a meta-analysis of case-control studies","volume":"11","author":"Hashemi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2020.11.035_bib21","doi-asserted-by":"crossref","first-page":"45124","DOI":"10.1038\/srep45124","article-title":"Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients","volume":"7","author":"Nomizo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.11.035_bib22","doi-asserted-by":"crossref","first-page":"17085","DOI":"10.1038\/s41598-019-53327-7","article-title":"Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab","volume":"9","author":"Funazo","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.11.035_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.035_bib24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy","volume":"26","author":"Liu","year":"2020","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.11.035_bib25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.11.035_bib26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.11.035_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1172\/JCI96113","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.11.035_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.humpath.2017.08.016","article-title":"Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma","volume":"68","author":"Yeo","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ejca.2020.11.035_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00262-016-1936-0","article-title":"A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer","volume":"66","author":"Tao","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2020.11.035_bib30","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/s41598-020-60437-0","article-title":"Hyperprogression under immune checkpoint inhibitor: a potential role for germinal immunogenetics","volume":"10","author":"Refae","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.11.035_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret\u00a0ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2020.11.035_bib32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Canc Cell"},{"key":"10.1016\/j.ejca.2020.11.035_bib33","doi-asserted-by":"crossref","first-page":"25952","DOI":"10.1038\/srep25952","article-title":"PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.11.035_bib34","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.035_bib35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.11.035_bib36","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.11.035_bib37","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.035_bib38","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.11.035_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci Immunol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:44Z","timestamp":1760733224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"alternative-id":["S0959804920313721"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}